Genetically engineered hepatitis c virus (hcv) nucleic acid clone, plasmid clone that houses a life-size hcv cdna, dna or rna transcribed from the full-length hcv cdna, transfected and in vitro infected host cell line with hcv, non-human animal infected with hcv, hcv viral particle, in vitro test system, hcv cell free, hcv vaccine and hcv test set and processes for identifying a cell line that is permissive and an animal that is permissive for hcv infection, to select hcv with adaptive mutations that allow higher levels of hcv replication in a permissive cell line, to infect an animal with hcv, to spread hcv in vitro, to transduce an animal susceptible to hcv infection with a heterologous gene, to produce hcv viral particles, hcv particle proteins and hcv antibodies, to separate agents capable of to modulate hcv replication, to prepare a hcv nucleic acid and to detect hcv antibodies in a biological sample from a patient.

摘要

"VIRUS NUCLEIC ACID CLONE GIVES GENETICALLY ENGINEERED HEPATITIS C (HCV), PLASMIDIC CLONE THAT HOUSES A NATURALLY SIZE HCV CDNA, DNA OR HCV RNA TRANSCRIBED FROM THE NATURAL LENGTH, CUTLERY LINING AND CUTTING LIGHT LINING AND CUTTING LINES. HCV INFECTED, NON-HUMAN ANIMAL INFECTED WITH HCV, HCV VIRAL PARTICLE, IN VITRO TEST SYSTEM, HCV CELL FREE, HCV VACCINE AND HCV TEST SET AND PROCESS TO IDENTIFY A CELL LINE. is PERMISSIVE AND AN ANIMAL THAT IS PERMISSIVE FOR HCV INFECTION, TO SELECT HCV WITH ADAPTIVE CHANGES THAT ALLOW HIGHER LEVELS OF HCV REPLICATION IN A PERMISSIVE CELL LINE, TO INFECT AN ANIMAL WITH HCV, TO INJECT , TO TRANSDUCT AN ANIMAL SUSTAINABLE TO HCV INFECTION WITH A HETEROLOGIST GENE, TO PRODUCE VIRAL HCV PARTICLES, HCV PARTICLE PROTEINS AND HCV ANTIBODIES, TO SEPARATE CAPABLE AGENTS TO MODULATE HCV REPLICATION, TO PREPARE AN HCV NUCLEIC ACID AND TO DETECT HCV ANTIBODIES IN A PATIENT'S BIOLOGICAL SAMPLE ". The present invention concerns the determination of RNA sequences from the authentic HCV genome, the construction of infectious HCV DNA clones, and the use of clones, or their derivatives in therapeutic, vaccine, and diagnostic applications. The invention is also directed to HCV vectors, for example, to human vaccine agent therapy.